Back
Legend Biotech Corporation (LEGN)
BiotechnologyLEGN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$21.82
+2.56%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-0.81
ROE
-25.2%
Gross margin
55.0%
Debt/Equity
0.40x
Revenue growth
56.5%
Legend Biotech Corporation — company intelligence
Earnings surprises
Q2 2026$0.09 vs $0.08 est+17.8%
Q1 2026$-0.30 vs $-0.02 est-1295.3%
Q4 2025$-0.16 vs $-0.11 est-44.5%
Q3 2025$-0.22 vs $-0.09 est-155.5%
Analyst consensus · 23 analysts
18 Buy5 Hold0 Sell
Updated Aug 7, 2026
Insider activity · 90 days
0 buys1 sellnet -6,000 shares
Casey Patrick JohnSell 6,000 · Jun 30, 2026
Huang Yinggift 3,382 · Jun 30, 2026
Recent SEC filings
4 — Insider transaction reportAug 18, 2026
4 — Insider transaction reportJul 2, 2026
4 — Insider transaction reportJul 2, 2026
Latest news
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49 — Benzinga · 1w ago
TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24 — Benzinga · 1w ago
Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40 — Benzinga · 1w ago
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58 — Benzinga · 1w ago
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78 — Benzinga · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.